Antibiotic Treatment in End Stage Cancer Patients; Advantages and Disadvantages.

IF 2.4 Q2 MATHEMATICAL & COMPUTATIONAL BIOLOGY

Cancer Informatics Pub Date : 2023-01-01 DOI:10.1177/11769351231161476

Tahmasebi Mamak, Hosamirudsari Hadiseh, Familrashtian Shirin, Parash Masoud, Salehi Mohammadreza, Abbaszadeh Mahsa

{"title":"Antibiotic Treatment in End Stage Cancer Patients; Advantages and Disadvantages.","authors":"Tahmasebi Mamak, Hosamirudsari Hadiseh, Familrashtian Shirin, Parash Masoud, Salehi Mohammadreza, Abbaszadeh Mahsa","doi":"10.1177/11769351231161476","DOIUrl":null,"url":null,"abstract":"Aim: In this study our aim was to elucidate whether advanced cancer patients benefit from antibiotic treatment in the last days of life in addition to reviewing the relevant costs and effects.Materials and methods: We reviewed medical records from 100 end-stage cancer patients and their antibiotic use during the hospitalization in Imam Khomeini hospital. Patient's medical records were analyzed retrospectively for cause and periodicity of infections, fever, increase in acute phase proteins, cultures, type and cost of antibiotic.Results: Microorganisms were found in only 29 patients (29%) and the most microorganism among the patients was E. coli (6%). About 78% of the patients had clinical symptoms. The highest dose of antibiotics was related to Ceftriaxone (40.2%) and in the second place was Metronidazole (34.7%) and the lowest dose was related to Levofloxacin, Gentamycin and Colistin (1.4%). Fifty-one patients (71%) did not have any side effects due to antibiotics. The most common side effect of antibiotics among patients was skin rash (12.5%). The average estimated cost for antibiotic use was 7 935 540 Rials (24.4 dollars).Conclusion: Prescription of antibiotics was not effective in symptom control in advanced cancer patients. The cost of using antibiotics during hospitalization is very high and also the risk of developing resistant pathogens during admission should be considered. Antibiotic side effects also occur in patients, causing more harm to the patient at the end of life. Therefore, the benefits of antibiotic advice in this time is less than its negative effects.","PeriodicalId":35418,"journal":{"name":"Cancer Informatics","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1f/9b/10.1177_11769351231161476.PMC10064464.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Informatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11769351231161476","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATHEMATICAL & COMPUTATIONAL BIOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Aim: In this study our aim was to elucidate whether advanced cancer patients benefit from antibiotic treatment in the last days of life in addition to reviewing the relevant costs and effects.

Materials and methods: We reviewed medical records from 100 end-stage cancer patients and their antibiotic use during the hospitalization in Imam Khomeini hospital. Patient's medical records were analyzed retrospectively for cause and periodicity of infections, fever, increase in acute phase proteins, cultures, type and cost of antibiotic.

Results: Microorganisms were found in only 29 patients (29%) and the most microorganism among the patients was E. coli (6%). About 78% of the patients had clinical symptoms. The highest dose of antibiotics was related to Ceftriaxone (40.2%) and in the second place was Metronidazole (34.7%) and the lowest dose was related to Levofloxacin, Gentamycin and Colistin (1.4%). Fifty-one patients (71%) did not have any side effects due to antibiotics. The most common side effect of antibiotics among patients was skin rash (12.5%). The average estimated cost for antibiotic use was 7 935 540 Rials (24.4 dollars).

Conclusion: Prescription of antibiotics was not effective in symptom control in advanced cancer patients. The cost of using antibiotics during hospitalization is very high and also the risk of developing resistant pathogens during admission should be considered. Antibiotic side effects also occur in patients, causing more harm to the patient at the end of life. Therefore, the benefits of antibiotic advice in this time is less than its negative effects.

Abstract Image

查看原文本刊更多论文

终末期癌症患者的抗生素治疗优点和缺点。

目的:在本研究中，我们的目的是阐明晚期癌症患者在生命的最后几天是否受益于抗生素治疗，并回顾相关的成本和效果。材料和方法:我们回顾了伊玛目霍梅尼医院100例晚期癌症患者的医疗记录及其住院期间的抗生素使用情况。回顾性分析患者病历中感染的原因和周期性、发热、急性期蛋白升高、培养、抗生素种类和费用。结果:29例患者检出微生物(29%)，其中大肠杆菌检出最多(6%)。约78%的患者有临床症状。抗生素使用剂量最高的是头孢曲松(40.2%)，其次是甲硝唑(34.7%)，最低的是左氧氟沙星、庆大霉素和粘菌素(1.4%)。51例(71%)患者未出现抗生素副作用。抗生素最常见的副作用是皮疹(12.5%)。抗生素使用的平均估计费用为7 935 540里亚尔(24.4美元)。结论:抗生素处方不能有效控制晚期肿瘤患者的症状。住院期间使用抗生素的费用非常高，入院期间发生耐药病原体的风险也应予以考虑。抗生素的副作用也会发生在病人身上，在病人生命的最后阶段对他们造成更大的伤害。因此，在这个时候，抗生素建议的好处小于它的负面影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Informatics Medicine-Oncology

CiteScore

3.00

自引率

5.00%

发文量

审稿时长

8 weeks

期刊介绍： The field of cancer research relies on advances in many other disciplines, including omics technology, mass spectrometry, radio imaging, computer science, and biostatistics. Cancer Informatics provides open access to peer-reviewed high-quality manuscripts reporting bioinformatics analysis of molecular genetics and/or clinical data pertaining to cancer, emphasizing the use of machine learning, artificial intelligence, statistical algorithms, advanced imaging techniques, data visualization, and high-throughput technologies. As the leading journal dedicated exclusively to the report of the use of computational methods in cancer research and practice, Cancer Informatics leverages methodological improvements in systems biology, genomics, proteomics, metabolomics, and molecular biochemistry into the fields of cancer detection, treatment, classification, risk-prediction, prevention, outcome, and modeling.